Hepatocellular carcinomas with intracellular hyaline bodies have a poor prognosis

Liver International

Volumn 37, Issue 4, 2017, Pages 600-610

  Aigelsreiter, Ariane ^a   Neumann, Jens ^a,b   Pichler, Martin ^a   Halasz, Judith ^c   Zatloukal, Kurt ^a   Berghold, Andrea ^a   Douschan, Philipp ^a   Rainer, Florian ^a   Stauber, Rudolf ^a   Haybaeck, Johannes ^a   Denk, Helmut ^a   Lackner, Carolin ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF MUNICH   (Germany)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

autophagy; hepatocellular carcinoma; intracellular hyaline body; Mallory Denk body; prognosis

Indexed keywords

SEQUESTOSOME 1; UBIQUITIN; CYTOKERATIN 18; CYTOKERATIN 8; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SQSTM1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL BODY; CELL INCLUSION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; INTRACELLULAR HYALINE BODY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALLORY DENK BODY; MIDDLE AGED; MONONUCLEAR CELL; NEUTROPHIL; OVERALL SURVIVAL; STEATOSIS; SURVIVAL ANALYSIS; AGED; AUSTRIA; AUTOPHAGY; LIVER; LIVER CELL; LIVER TUMOR; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; AUSTRIA; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; KERATIN-18; KERATIN-8; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SEQUESTOSOME-1 PROTEIN; SURVIVAL ANALYSIS;

EID: 85016515068     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13325     Document Type: Article

References (39)

1. Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: where are we? World J Exp Med. 2016;6:21–36.
2. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
3. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.
4. Sutcliffe R, Maguire D, Portmann B, et al. Selection of patients with hepatocellular carcinoma for liver transplantation. Br J Surg. 2006;93:11–18.
5. Zimmerman MA, Ghobrial RM, Tong MJ, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg. 2008;143:182–188.
6. Kang JY, Choi MS, Kim SJ, et al. Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma. Korean J Hepatol. 2010;16:383–388.
7. Mann CD, Neal CP, Garcea G, et al. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007;43:979–992.
8. Zatloukal K, French SW, Stumptner C, et al. From Mallory to Mallory-Denk bodies: what, how and why? Exp Cell Res. 2007;313:2033–2049.
9. Theise ND, Curado MP, Franceschi S, et al. Hepatocellular carcinoma. WHO Classification of Tumors of the Digestive System. Lyon: International Agency for Research on Cancer (IARC); 2010.
10. Denk H, Stumptner C, Fuchsbichler A, et al. Are the Mallory bodies and intracellular hyaline bodies in neoplastic and non-neoplastic hepatocytes related? J Pathol. 2006;208:653–661.
11. Komatsu M, Waguri S, Koike M, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell. 2007;131:1149–1163.
12. Nezis IP, Simonsen A, Sagona AP, et al. Ref(2)P, the Drosophila melanogaster homologue of mammalian p62, is required for the formation of protein aggregates in adult brain. J Cell Biol. 2008;180:1065–1071.
13. Inami Y, Waguri S, Sakamoto A, et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol. 2011;193:275–284.
14. Komatsu M, Kurokawa H, Waguri S, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol. 2010;12:213–223.
15. Bao L, Chandra PK, Moroz K, et al. Impaired autophagy response in human hepatocellular carcinoma. Exp Mol Pathol. 2014;96:149–154.
16. Ding ZB, Shi YH, Zhou J, et al. Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res. 2008;68:9167–9175.
17. Sobin L, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumors, 7th edn. Singapore: Wiley-Blackwell; 2009.
18. Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850–855.
19. Salomao M, Yu WM, Brown RS Jr, et al. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol. 2010;34:1630–1636.
20. Stumptner C, Heid H, Fuchsbichler A, et al. Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma. Demonstration of p62 as major constituent. Am J Pathol. 1999;154:1701–1710.
21. Stumptner C, Fuchsbichler A, Zatloukal K, et al. In vitro production of Mallory bodies and intracellular hyaline bodies: the central role of sequestosome 1/p62. Hepatology. 2007;46:851–860.
22. Harada M, Kumemura H, Omary MB, et al. Proteasome inhibition induces inclusion bodies associated with intermediate filaments and fragmentation of the Golgi apparatus. Exp Cell Res. 2003;288:60–69.
23. Harada M, Strnad P, Resurreccion EZ, et al. Keratin 18 overexpression but not phosphorylation or filament organization blocks mouse Mallory body formation. Hepatology. 2007;45:88–96.
24. Bardag-Gorce F, Vu J, Nan L, et al. Proteasome inhibition induces cytokeratin accumulation in vivo. Exp Mol Pathol. 2004;76:83–89.
25. Denk H, Krepler R, Lackinger E, et al. Biochemical and immunocytochemical analysis of the intermediate filament cytoskeleton in human hepatocellular carcinomas and in hepatic neoplastic nodules of mice. Lab Invest. 1982;46:584–596.
26. Mathew R, Karp CM, Beaudoin B, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell. 2009;137:1062–1075.
27. Moscat J, Diaz-Meco MT. P62: a versatile multitasker takes on cancer. Trends Biochem Sci. 2012;37:230–236.
28. Kuo WL, Sharifi MN, Lingen MW, et al. p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors. PLoS ONE. 2014;9:e90171.
29. Liu JL, Chen FF, Lung J, et al. Prognostic significance of p62/SQSTM1 subcellular localization and LC3B in oral squamous cell carcinoma. Br J Cancer. 2014;111:944–954.
30. Wang X, Du Z, Li L, et al. Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome. Int J Clin Exp Pathol. 2015;8:10644–10652.
31. Schläfli AM, Adams O, Galvan JA, et al. Prognostic value of the autophagy markers LC3 and p62/SQSTM1 in early-stage non-small cell lung cancer. Oncotarget. 2016;7:39544–39555.
32. Inoue D, Suzuki T, Mitsuishi Y, et al. Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci. 2012;103:760–766.
33. Park JM, Huang S, Wu TT, et al. Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther. 2013;14:100–107.
34. Mohamed A, Ayman A, Deniece J, et al. P62/Ubiquitin IHC expression correlated with clinicopathologic parameters and outcome in gastrointestinal carcinomas. Front Oncol. 2015;5:1–7.
35. Hoso M, Nakanuma Y. Clinicopathological characteristics of hepatocellular carcinoma bearing Mallory bodies: an autopsy study. Liver. 1990;10:264–268.
36. Salomao M, Remotti H, Vaughan R, et al. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol. 2012;43:737–746.
37. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11–20.
38. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181–200.
39. Starmann J, Falth M, Spindelboeck W, et al. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS ONE. 2012;7:e46584.